2018
Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes
Goldstein S, Mentz R, Hellkamp A, Randolph T, Fonarow G, Hernandez A, Yancy C, Al‐Khatib S. Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. Clinical Cardiology 2018, 42: 256-263. PMID: 30548280, PMCID: PMC6386168, DOI: 10.1002/clc.23135.Peer-Reviewed Original ResearchConceptsCardiac resynchronization therapy implantationCardiac resynchronization therapyHF re-hospitalizationHeart failureRe-hospitalizationHF hospitalizationCardiac resynchronization therapy device implantationOutcome of all-cause mortalityTime of CRT implantationAssociated with clinical outcomesAssociated with similar benefitsAll-cause mortalityAssociated with lower ratesHeart failure patientsCRT implantationResynchronization therapyClinical outcomesHF patientsDevice implantationFailure patientsCenters for MedicarePatientsDelayed implantationReduce mortalityMedicaid Services data
2017
Relationship Between Peak Troponin Values and Long‐Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes
Goldstein S, Newby L, Cyr D, Neely M, Lüscher T, Brown E, White H, Ohman E, Roe M, Hamm C. Relationship Between Peak Troponin Values and Long‐Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. Journal Of The American Heart Association 2017, 6: e005334. PMID: 28400368, PMCID: PMC5533023, DOI: 10.1161/jaha.116.005334.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedBiomarkersChi-Square DistributionClopidogrelDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLinear ModelsMaleMiddle AgedMultivariate AnalysisNon-ST Elevated Myocardial InfarctionPlatelet Aggregation InhibitorsPrasugrel HydrochlorideProportional Hazards ModelsRisk FactorsTiclopidineTime FactorsTreatment OutcomeTroponinUp-RegulationConceptsNon-ST-segment elevation ACS patientsLong-term ischemic eventsACS patientsDiabetes mellitus prevalenceTroponin levelsBody mass indexStatistically significant heterogeneityGRACE risk scoreHeterogeneity of treatment effectsIschemic eventsIndex ACS eventACS eventsNon-ST-segment elevation ACSMedically managed patientsComposite end pointLong-term outcomesMass indexTreatment effectsRisk scorePeak troponin valuesPercutaneous coronary interventionSignificant heterogeneityStatistically significant differenceManaging patientsPeak troponin